Advertisement

Journal of Neurology

, Volume 256, Issue 3, pp 374–381 | Cite as

Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities

  • H. Tremlett
  • Y. Zhao
  • V. Devonshire
  • and the UBC Neurologists
ORIGINAL COMMUNICATION

Abstract

Background

Similarities in the onset age of progression in secondary-progressive (SP) and primary-progressive multiple sclerosis (PPMS) have been previously reported. However, with longer follow-up, more relapsing-remitting (RRMS) patients reach SPMS, such that the baseline characteristics, including age at progression may shift. We aimed to examine how this phenomenon impacts on demographic and clinical comparisons made between PP and SPMS.

Methods and results

Patients with definite MS, onset by July 1988 and ≥ 1 Expanded Disability Status Scale (EDSS) score were selected from the British Columbia-wide MS database (n = 2837). Of these, 353 (12.4 %) had PPMS and 1445/2484 (58.2 %) of the RRMS population reached SPMS at study close (July 2003). Females predominated in the SPMS population regardless of follow-up time (p ≤ 0.032). From Kaplan-Meier analysis (all RR, SP and PP patients considered), the estimated median onset age of progression was greater in SPMS (49.0 years; 95 % CI: 48.3–49.7) than PPMS (41.0 years; 95 % CI: 39.7–42.4), p < 0.0005. If the RR patients (who had not developed SPMS) were excluded, median age of onset of SPMS was still greater (43.1 years (95 % CI: 42.3–43.9, p < 0.0005).

Conclusions

Although there were some similarities between SPMS and PPMS, the former had a later onset age in our British Columbian MS cohort.

Key words

multiple sclerosis natural history secondary-progression primary-progression survival analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Canada Statistics (1996) Population by selected ethnic origins, by provinces and territories: Census (online). Available at: http://www.statcan.ca/english/ Pgdb/demo28c.htm 1996; Accessed January 4, 2007Google Scholar
  2. 2.
    Confavreux C (2006) Chapter 4: The natural history of MS. In: Compston A, et al. (eds) McAlpine’s Multiple Sclerosis. Churchill Livingstone Elsevier, Philadelphia, pp 205–206Google Scholar
  3. 3.
    Confavreux C, Vukusic S (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129:606–616PubMedCrossRefGoogle Scholar
  4. 4.
    Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430–1438PubMedCrossRefGoogle Scholar
  5. 5.
    Cottrell DA, Kremenchutzky M, Rice GP, Koopman WJ, Hader W, Baskerville J, Ebers GC (1999) The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 122:625–639PubMedCrossRefGoogle Scholar
  6. 6.
    Koch M, Mostert J, Heersema D, De Keyser J (2007) Progression in multiple sclerosis: further evidence of an age dependent process. J Neurol Sci 255:35–41PubMedCrossRefGoogle Scholar
  7. 7.
    Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC (2006) The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease. Brain 129:584–594PubMedCrossRefGoogle Scholar
  8. 8.
    Kurtzke J (1983) Rating neurologic impairment in Multiple Sclerosis: An expanded disability status scale (EDSS). Neurology 33:1444–1452PubMedGoogle Scholar
  9. 9.
    Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911PubMedGoogle Scholar
  10. 10.
    McAlpine D, Compston N (1952) Some aspects of the natural history of disseminated sclerosis. Q J Med 21:135–167PubMedGoogle Scholar
  11. 11.
    Minderhoud JM, van der Hoeven JH, Prange AJ (1988) Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study. Acta Neurol Scand 78:10–15PubMedCrossRefGoogle Scholar
  12. 12.
    Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New Diagnostic Criteria for Multiple Sclerosis: guidelines for research proposals. Ann Neurol 13:227–231PubMedCrossRefGoogle Scholar
  13. 13.
    Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M (2006) Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 5:343–354PubMedCrossRefGoogle Scholar
  14. 14.
    Runmarker B, Andersen O (1993) Prognostic factors in a Multiple Sclerosis incidence cohort with 25 years of follow-up. Brain 116:117–134PubMedCrossRefGoogle Scholar
  15. 15.
    Sadovnick AD, Ebers GC, Wilson RW, Paty DW (1992) Life expectancy in patients attending multiple sclerosis clinics. Neurology 42:991–994PubMedGoogle Scholar
  16. 16.
    Sweeney VP, Sadovnick AD, Brandejs V (1986) Prevalence of Multiple Sclerosis in British Columbia, Canada. Can J Neurol Sci 13:47–51PubMedGoogle Scholar
  17. 17.
    Tremlett H, Paty D, Devonshire V (2006) Disability progression in multiple sclerosis is slower than previously reported. Neurology 66:172–177PubMedCrossRefGoogle Scholar
  18. 18.
    Tremlett H, Paty D, Devonshire V (2005) The natural history of primary progressive MS in British Columbia, Canada. Neurology 65:1914–1923CrossRefGoogle Scholar
  19. 19.
    Tremlett H, Zhao Y, Devonshire V (2008) The natural history of secondary- progressive multiple sclerosis. Multiple Sclerosis 14:314–324PubMedCrossRefGoogle Scholar
  20. 20.
    Weinshenker BG (2001) Bayesian analysis: what does it add to studies of the natural history of MS? J Neurol Sci 189:1–2PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2009

Authors and Affiliations

  • H. Tremlett
    • 1
    • 2
  • Y. Zhao
    • 3
  • V. Devonshire
    • 1
  • and the UBC Neurologists
  1. 1.Dept. of Medicine (Neurology), rm S1782211 Wesbrook Mal, University of British ColumbiaVancouverCanada
  2. 2.Faculty of Medicine, (Health Care and Epidemiology)University of British ColumbiaVancouverCanada
  3. 3.MS/MRI Research GroupUniversity of British ColumbiaVancouverCanada

Personalised recommendations